Middle East And Africa Peripheral Liquid Embolic Agents Market (2026 - 2036)

Middle East And Africa Peripheral Liquid Embolic Agents Market Summary

The Middle East and Africa peripheral liquid embolic agents market size was valued at USD 19.5 million in 2025 and is projected to grow from USD 21.3 million in 2026 to USD 49.6 million by 2036, at a CAGR of 8.8% from 2026 to 2036. The market is driven by the rising prevalence of peripheral vascular disorders, increasing adoption of minimally invasive endovascular procedures, and growing use of embolization techniques in interventional oncology.

Increasing diagnosis and treatment of venous disorders is driving the use of peripheral liquid embolic agents across the Middle East, particularly for patients requiring minimally invasive endovascular procedures. Varicose veins account for a substantial proportion of venous disease cases, with factors such as aging, obesity, prolonged standing, physical inactivity, pregnancy, and chronic venous insufficiency contributing to the need for clinical intervention.

For instance, a study published by the MDPI in 2025, titled "Prevalence of Varicose Veins Among Teaching Professionals and Their Impact on Quality of Life and Job Performance." A cross-sectional study was conducted employing a stratified convenience sampling strategy among 400 school and university educators across different regions of Saudi Arabia. Data collection took place over four months, from mid-January to the end of April 2025.

Factors Associated with the Prevalence of Varicose Veins (VV) among Teaching Professionals (n = 400)

Source: MDPI 2025

In addition, expansion of healthcare infrastructure and investment in interventional facilities: The expansion of healthcare infrastructure across the Middle East is supporting the adoption of advanced minimally invasive and image-guided procedures, including embolization interventions. For instance, in February 2026, Aster DM Healthcare announced a Dh1 billion investment in the UAE to expand its healthcare network, including the development of two new hospitals, capacity expansion at an existing facility, and the introduction of advanced medical services. The investment is expected to add approximately 372 beds and create more than 1,000 jobs over the next two to three years. Such investments are strengthening the region's hospital capacity and improving access to specialized and technology-intensive healthcare services. The expansion of advanced clinical infrastructure is expected to increase the availability of facilities capable of performing complex catheter-based and image-guided interventions, thereby creating opportunities for greater adoption of peripheral liquid embolic agents in the UAE and wider Middle East market.

Market Dynamics

The Middle East and Africa peripheral liquid embolic agents market is primarily driven by the increasing adoption of minimally invasive endovascular procedures, expansion of interventional radiology services, and growing demand for image-guided treatment of complex vascular conditions. Healthcare providers are adopting catheter-based approaches as alternatives to open surgery for selected cases involving peripheral vascular hemorrhage, vascular malformations, aneurysms, hypervascular tumors, and venous disorders. The expansion of specialized hospitals, angiography facilities, and interventional radiology units is improving physicians' ability to perform selective and complex embolization procedures.

Market Characteristics & Concentration

The Middle East and Africa peripheral liquid embolic agents industry is characterized by a moderate to high degree of innovation, supported by advancements in liquid embolic formulations, delivery systems, viscosity, polymerization characteristics, and catheter compatibility. Manufacturers and clinical users are focused on technologies that enable controlled delivery, predictable vessel occlusion, improved visualization, and treatment of complex or tortuous vascular anatomy.

The market is characterized by a low to moderate level of M&A activity, with companies primarily seeking to strengthen their interventional radiology and vascular portfolios through strategic partnerships, distribution agreements, licensing arrangements, and selective acquisitions. These activities can provide access to complementary embolization technologies, local regulatory expertise, established hospital relationships, and regional distribution networks. Partnerships are particularly important in the Middle East and Africa because market access varies considerably across countries.

The market experiences a high regulatory impact because peripheral liquid embolic agents are specialized medical devices that require compliance with country-specific requirements related to safety, performance, clinical evidence, manufacturing quality, product registration, and post-market surveillance. Regulatory pathways differ across major MEA markets, including North Africa, South Africa, and other countries. These differences can increase registration costs, documentation requirements, distributor qualification requirements, and time to market.

The market faces moderate to high competition from substitute embolization technologies, including embolization coils, vascular plugs, particles, sclerosants, and other embolic materials. Product selection depends on vessel size, lesion characteristics, vascular anatomy, desired permanence of occlusion, procedural urgency, and physician preference. Coils and vascular plugs are commonly used for focal vessel occlusion, while particles and other agents may be selected for tumor embolization and specific vascular indications.

Demand for peripheral liquid embolic agents in the Middle East and Africa is highly concentrated in hospitals, academic medical centers, tertiary-care hospitals, and specialized interventional radiology and vascular centers. These facilities generally have angiography systems, advanced imaging equipment, catheterization laboratories, microcatheters, and trained specialists required for complex embolization procedures. Concentration is particularly evident in developed healthcare markets such as Saudi Arabia and the UAE, while adoption in several African and lower-resource markets remains more limited because of infrastructure, specialist availability, and equipment constraints.

Analyst Perspective

From an analyst’s perspective, the market is positioned for steady growth, supported by expanding interventional radiology infrastructure and increasing adoption of minimally invasive embolization. Opportunities are expected across hemorrhage, hypervascular tumors, AVMs, aneurysms/pseudoaneurysms, Type II endoleaks, PVE, and venous applications. Advances in EVOH and cyanoacrylate-based agents, delivery systems, and imaging technologies are expected to improve procedural control and clinical adoption. Manufacturers offering controlled delivery, radiopacity, biocompatibility, predictable occlusion, and strong clinical evidence are likely to gain an advantage. Growing tertiary hospitals, specialist training, vascular centers, and private healthcare investment will further support market penetration.

Product Insights

The Ethylene Vinyl Alcohol Copolymer (EVOH) segment dominated the market, accounting for 85.6% in 2025. The segment’s dominance is supported by the increasing use of EVOH-based non-adhesive liquid embolic agents in complex embolization procedures, particularly in advanced healthcare centers across Saudi Arabia, the UAE, and Qatar. EVOH-based agents offer controlled delivery, cohesive embolization, and radiopacity, making them suitable for peripheral hemorrhage, vascular malformations, and hypervascular tumors.

Cyanoacrylates/tissue glues combined segment is expected to witness fastest growth during the forecast period, driven by increasing demand for rapid and permanent vascular occlusion in emergency hemorrhage management and complex vascular lesions across the Middle East & Africa. Growing adoption of minimally invasive embolization procedures, expansion of interventional radiology capabilities, and increasing availability of image-guided vascular interventions are supporting the use of liquid embolic agents in regional healthcare facilities. n-Butyl cyanoacrylate (n-BCA) rapidly polymerizes upon contact with blood, enabling immediate and durable vessel occlusion, making it particularly suitable for small-caliber, tortuous, and high-flow vessels where rapid hemostasis is required.

Application Insights

The venous applications segment dominated market, accounting for 40.1% of the market in 2025. This dominance supported by the growing use of minimally invasive embolization procedures for conditions such as varicocele, pelvic congestion syndrome (PCS), and varicose veins. In South Africa, Fertility Solutions, in an article published on April 2026, reported that male factor infertility accounts for approximately 40% of South African couples struggling to conceive, while varicocele is present in approximately 40% of men investigated for infertility. These figures indicate a substantial underlying patient population for venous interventions such as varicocele embolization and support the demand potential for peripheral liquid embolic agents in the region.

Type II endoleaks is expected to grow at the fastest rate during the forecast period, driven by the increasing adoption of EVAR for abdominal aortic aneurysms and the occurrence of Type II endoleaks following these procedures. Type II endoleaks are the most common type of endoleak and require secondary embolization when persistent blood flow is associated with aneurysm sac enlargement. The growing adoption of minimally invasive endovascular procedures and advancements in liquid embolic technologies are supporting their use in the management of complex endoleaks. Liquid embolic agents, including ethylene-vinyl alcohol copolymers and n-butyl cyanoacrylate, can penetrate the endoleak cavity and small collateral vessels, providing an effective treatment option when selective catheterization of all feeding vessels is challenging.

End Use Insights

The hospitals segment dominated the market, accounting for 57.2% in 2025. The segment is supported by continued expansion of specialized healthcare infrastructure and increasing investment in facilities capable of providing minimally invasive procedures. For instance, in July 2026, Burjeel Holdings announced that it plans to expand its presence in Saudi Arabia through specialized day surgery centers, with the first facility planned for Khobar in early 2027, followed by Riyadh later in the year. The two centers are expected to involve approximately USD 100 million in investment, with the company targeting a potential network of up to 8-10 day surgery centers in Saudi Arabia. The expansion of specialized surgical and outpatient facilities is expected to increase access to minimally invasive vascular and interventional procedures, thereby supporting the adoption of peripheral liquid embolic agents across hospitals and specialized healthcare facilities in the region.

The others end use segment is expected to grow at the fastest rate during the forecast period. Growth is supported by the increasing adoption of outpatient interventional procedures, office-based laboratories (OBLs), ambulatory surgery centers (ASCs), and specialized vascular treatment facilities. The shift toward outpatient and same-day care is gaining momentum across the Middle East, particularly in Middle East, as healthcare providers expand specialized facilities designed to deliver minimally invasive procedures with shorter recovery times.

Country Insights

The Middle East peripheral liquid embolic agents market held the largest share 53.2% in 2025, supported by the region’s substantial cardiovascular disease burden and growing need for minimally invasive vascular interventions. For instance, Kuwait recorded an increase in cardiovascular disease prevalence from 258,385.0 in 2021 to 311,275.5 in 2024, while incidence increased from 18,167.9 to 22,014.8 during the same period, indicating a growing patient population requiring vascular disease management and supporting demand for minimally invasive embolization procedures. The continued burden of cardiovascular disease, combined with increasing availability of interventional radiology and image-guided vascular procedures, is expected to support adoption of peripheral liquid embolic agents across Middle Eastern healthcare systems.

North Africa Peripheral Liquid Embolic Agents Market Trends

The peripheral liquid embolic agents market in North Africa is witnessing the fastest rate during the forecast period, supported by the increasing adoption of minimally invasive endovascular procedures for managing complex peripheral vascular conditions, including peripheral vascular malformations/AVMs, aneurysms, pseudoaneurysms, peripheral vascular hemorrhage, portal vein embolization, and venous applications such as varicocele and pelvic venous disorders. The region is experiencing gradual development of vascular care infrastructure, with improved availability of angiography systems, interventional radiology facilities, and specialized clinicians capable of performing catheter-based embolization procedures.

Key Middle East And Africa Peripheral Liquid Embolic Agents Company Insights

Some of the key companies in the market include Medtronic, BALT Group (via Compass Medical Pty Ltd), and GEM S.r.l. (H.B. Fuller Company). Major players in the Middle East and Africa market are focusing on product innovation and development of advanced formulations with improved delivery control, penetration, visibility, and safety.

Key Middle East and Africa Peripheral Liquid Embolic Agents Companies

• Medtronic

• GEM S.r.l. (H.B. Fuller Company)

• BALT Group (via Compass Medical Pty Ltd)

Competitive Benchmarking

Middle East And Africa Peripheral Liquid Embolic Agents Market Report Scope

Middle East and Africa Peripheral Liquid Embolic Agents Market Report Segmentation

This report forecasts revenue growth at country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2036. For this study, Grand View Research has segmented the Middle East and Africa peripheral liquid embolic agents market report based on product, application and end use:

• Product Outlook (Revenue, USD Million, 2021 - 2036)

  • Ethylene Vinyl Alcohol Copolymer (EVOH)

  • Cyanoacrylates/tissue glues combined

  • n-butyl cyanoacrylate (n-BCA)

  • n-hexyl cyanoacrylate (n-HCA)

• Application Outlook (Revenue, USD Million, 2021 - 2036)

  • Peripheral Vascular Hemorrhage

  • Hypervascular Tumors

  • Peripheral Vascular Malformations/AVMs

  • Aneurysms/Pseudoaneurysms

  • Type II Endoleaks

  • Portal Vein Embolization (PVE)

  • Venous Applications (varicocele, PCS, varicose veins)

• End Use Outlook (Revenue, USD Million, 2021 - 2036)

  • Hospitals

  • Others

• Country Outlook (Revenue, USD Million, 2021-2036)

  • Middle East

  • North Africa

  • South Africa

Research Methodology

The Middle East and Africa peripheral liquid embolic agents market figures in this report are based on a proven research process that combines executive interviews with secondary research from proprietary databases, company filings, and recognized regulatory and institutional sources. Market size is built through value-chain sizing—reconciling supply-side and demand-side estimates—and triangulated with bottom-up and top-down approaches. Every estimate passes multiple levels of expert validation before publication, with each Middle East and Africa peripheral liquid embolic agents segment quantified using the revenue-capture definitions in the table below.

Segment Definition

Estimation Model

Customization Table

This report has been delivered with the following In-depth customizations